BeiGene (HKG:6160, SHA:688235) reported that its net loss for 2024 narrowed by 26.9% to $644.8 million from the $881.7 million loss a year earlier, according to a Thursday filing with the Hong Kong bourse.
Loss per share narrowed 27.7% to $0.47 from $0.65 loss per share a year ago.
Revenue rose 55.0% to $3.78 billion from $2.19 billion the previous year.
The company's shares were up 1% at the Hong Kong bourse while down less than 1% at the Shanghai bourse in recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。